Novartis Diovan Heart Failure Indication Covers 1.2-2.5 Million Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis will be targeting 1.2 mil. to 2.5 mil. patients with the August 14 approval of Diovan for "treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors."